AbCellera Biologics Inc. (ABCL)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
23.19+0.38 (+1.67%)
At close: 4:00PM EDT
| Previous close | 22.81 |
| Open | 22.80 |
| Bid | 23.20 x 1000 |
| Ask | 23.48 x 900 |
| Day's range | 22.35 - 23.40 |
| 52-week range | 22.34 - 71.91 |
| Volume | 2,929,406 |
| Avg. volume | 1,407,339 |
| Market cap | 6.283B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 13 May 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 51.20 |
- Business Wire
AbCellera Announces Secondary Private Sale of 11.9 Million Common Shares
AbCellera (Nasdaq: ABCL) today announced that certain entities owned and/or controlled, directly or indirectly, by Carl Hansen, Ph.D., Cofounder, Chief Executive Officer, and President of AbCellera, and other senior leaders (collectively, the "Selling Shareholders"), have entered into separate share purchase agreements with experienced institutional investors (the "Buyers"), pursuant to which the Buyers purchased an aggregate 11,900,000 common shares ("Shares"). Proceeds from the sale were paid
- Simply Wall St.
AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Just Cut Their EPS Forecasts Substantially
The analysts covering AbCellera Biologics Inc. ( NASDAQ:ABCL ) delivered a dose of negativity to shareholders today, by...
- Business Wire
CORRECTING and REPLACING AbCellera Reports Q1 2021 Business Results
AbCellera Reports Q1 2021 Business Results
© 2021 Verizon Media. All rights reserved.
